Explore the potential of SGLT2 inhibitors for IgAN. Learn how these diabetes drugs slow kidney damage progression when added to standard treatment.

Although both sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) ...

SGLT2 inhibitors prevented age-related kidney damage in a rapid-aging fish. Treatment preserved blood vessels, energy ...

Danish national registry data suggest adults with type 2 diabetes taking SGLT2 inhibitors have a slightly lower risk of developing diabetic foot problems than those taking GLP-1 receptor agonists.

Patients with SGLT2 inhibitor-associated diabetic ketoacidosis (DKA) received significantly lower doses of insulin in the first 24 hours of treatment compared with patients with type 1 diabetes DKA, ...

The use of SGLT2 inhibitors was not associated with a clear increase in overall UTI risk among patients with RA and diabetes.

The SGLT2 inhibitors market is experiencing robust growth, driven by the rising prevalence of type 2 diabetes and chronic kidney disease worldwide. Additionally, the expected launch of emerging SGLT2 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. “Sodium-glucose transport protein 2 (SGLT2) inhibitor ...

GLP-1 receptor agonist or SGLT2 inhibitor prescribing became more common for people with type 1 diabetes in recent years, a nationwide cross-sectional analysis found. From 2010 to 2023, the percentage ...

Please provide your email address to receive an email when new articles are posted on . GLP-1 receptor agonists conferred greater HbA1c reductions in older adults than younger adults. Older adults had ...

Sodium-glucose cotransporter 2 (SGLT2) inhibitors provide a beneficial choice of treatment for patients with type 2 diabetes (diabetes mellitus/T2DM). It can be used as an alternative for those who ...